TACE for pancreatic cancer is a selective, liver-directed treatment used in selected patients with liver metastases. The procedure delivers chemotherapy to vessels supplying the target tumour and uses embolization to reduce blood flow. The article covers treatment planning, the procedure, recovery, risks, goals, follow-up and current evidence, including German clinical experience, while explaining why TACE is not established as routine standard treatment.

TACE for Pancreatic Cancer: Liver-Directed Therapy and Treatment Experience

When pancreatic cancer spreads, the liver is a common site of distant metastasis. For selected patients, TACE offers a way to treat liver tumours directly through the vessels supplying them. The treatment is designed to deliver chemotherapy to the targeted area while reducing its blood supply.

TACE Treatment Approach for Pancreatic Cancer

Chemotherapy is delivered into vessels supplying the liver tumour, followed by embolization to reduce blood flow to the treated area. This increases local drug exposure and contributes to the treatment effect [1] [4]. 

• TACE combines arterial chemotherapy for pancreatic cancer delivery with targeted embolization to concentrate treatment within the liver tumor with the aim of increasing local chemotherapy exposure and reducing arterial blood flow to the treated tumor. 
• TACE directly treats targeted liver disease rather than cancer throughout the body.
• In pancreatic cancer, TACE has been studied mainly for liver metastases. It remains a selective treatment option and is not established as routine standard treatment. TACE is therefore a selective, non-routine locoregional treatment rather than an established standard treatment for metastatic pancreatic cancer.

Factors Shaping TACE Treatment Planning in Pancreatic Cancer

Deciding whether TACE is appropriate requires assessment of the liver disease, overall cancer status and technical feasibility. The interventional radiologist considers these factors within the multidisciplinary treatment plan:

• Imaging of the specific liver lesions being considered, to judge their number, size and position.
• The arterial anatomy supplying those lesions, since catheter access depends on it.
• Liver function, which affects how well the liver will tolerate the procedure.
• Previous cancer treatment and how the disease has behaved since.
• The spread of disease within the liver, to the extent it changes what TACE can realistically target.
• Overall medical fitness for an interventional procedure.

TACE Treatment Journey for Pancreatic Cancer: From Planning to Follow-Up

Treatment involves vascular mapping, chemotherapy delivery, embolization and follow-up followed by clinical and imaging follow-up.

Planning the Treatment Route

Planning starts with CT or MRI to define the liver lesions and their distribution to characterize the liver lesions, their distribution and the overall extent of disease. Angiography identifies the vessels supplying the target and guides selective catheter placement. Blood tests assess liver function and other factors relevant to procedural safety. The team then determines which lesions can be safely targeted. 

Delivering Chemotherapy and Embolizing the Target

On the day, vascular access is commonly obtained through the femoral artery under local anaesthetic with or without procedural sedation according to the procedure and patient factors. A catheter is guided toward the liver, and a smaller microcatheter is advanced selectively into vessels supplying the target lesion. Once in position, chemotherapy is delivered through the catheter and embolic material is introduced to reduce blood flow to the treated area. Imaging guides the procedure and helps direct treatment toward the target while limiting unnecessary treatment of healthy liver tissue [1].

Monitoring After TACE

After the procedure, patients are monitored for early side effects and complications. The duration of observation or hospital stay depends on the procedure and the patient's condition.

Goals of TACE Treatment in Pancreatic Cancer

TACE aims to control liver tumours that can be safely targeted. For selected patients, local control may reduce liver tumour burden or complement other treatments. TACE as a curative treatment for metastatic pancreatic adenocarcinoma and does not provide comprehensive treatment of extrahepatic or systemic disease.

TACE directly treats targeted liver disease and therefore does not replace systemic treatment for metastatic pancreatic cancer. A separate hepatic artery infusion study in pancreatic cancer liver metastases reported higher intrahepatic response with HAI plus systemic chemotherapy, but this was not a TACE study. The role of TACE depends on the extent of liver disease and the overall treatment plan [3] [4].

TACE Safety and Recovery in Pancreatic Cancer

TACE can cause side effects and complications. Recovery and safety risk vary according to the extent of embolization, tumor burden and distribution, baseline liver function, vascular anatomy, comorbidities and other patient- and procedure-specific factors.

Recovery After TACE

Many patients notice a cluster of short-lived effects in the days after treatment, sometimes grouped together as post-embolization syndrome. These can include:

• Pain or discomfort over the liver area, usually in the first day or two.
• Nausea, managed with anti-sickness medication when needed.
• Fatigue.
• A temporary drop in appetite.
• Fever can occur as part of post-embolization syndrome; persistent, high or otherwise concerning fever requires assessment for infection or another complication.

Patients are monitored immediately afterwards, and these effects usually ease within a few days with supportive care during early recovery.

TACE Risks and Complications

Less common complications include:

• More pronounced post-embolization effects that go beyond the usual short-term reaction.
• Bleeding, including at the arterial access site.
• Infection, such as an abscess forming in the treated area. The risk may be higher in patients with altered biliary anatomy or previous biliary interventions.
• Vascular complications, for example unintended blockage or injury of a blood vessel.
• Worsening liver function, particularly where liver reserve is already limited.
• Reactions including allergic-like reactions; contrast-associated kidney injury is a separate potential concern, particularly in patients with pre-existing renal impairment or other risk factors.

Serious complications are possible, and risk varies with the patient, tumour burden and procedure baseline liver function, vascular and biliary anatomy, comorbidities and the details of the procedure. No interventional procedure is entirely risk-free.

Factors Affecting TACE Safety

TACE safety depends on several factors, including liver function, tumour burden, vascular anatomy and the extent of treatment planned. Previous cancer treatment, overall health and the experience of the interventional radiology team can also influence how safely the procedure is performed.

Results and Evidence of TACE in Pancreatic Cancer

TACE has shown potential in selected patients with pancreatic cancer, but the available evidence is still based on relatively small patient groups.

Monitoring Response After TACE

Follow-up CT or MRI is used to assess the treated lesions for response, stability or progression. Because treated lesions can change in appearance after TACE, response may not be clear immediately. The findings help determine whether further TACE or another treatment should be considered.

Evidence for TACE in Pancreatic Cancer

A prospective randomized trial at University Hospital Frankfurt compared two TACE protocols for pancreatic cancer liver metastases. Among 26 patients completing three planned sessions, partial response was 15.4% with degradable starch microspheres alone versus 53.8% with added Lipiodol; no complete responses occurred. Median overall survival was 20 versus 23 months, with no significant difference between groups. The response analysis included only patients who completed three planned sessions, so these response rates may not represent all patients enrolled in the trial [1]. 

Other arterial approaches have also been studied in pancreatic cancer. A 2024 randomized phase II trial evaluated pancreatic arterial infusion (PAI) without embolization and found no significant difference in median overall survival compared with intravenous chemotherapy [2]. These findings relate to PAI rather than TACE and should not be used to estimate TACE outcomes.

Tumour response by TACE protocol in the Frankfurt randomised trial of pancreatic cancer liver metastases [1].

A 2026 Frankfurt study retrospectively evaluated TACE alone or with microwave ablation in 150 patients with unresectable pancreatic cancer. Its retrospective design and inclusion of both locally advanced and metastatic disease limit how directly the findings apply to pancreatic cancer liver metastases [5].

• Even the stronger trials involve small, carefully selected groups of patients.
• Patient selection differs between studies, which makes the results hard to generalise.
• Prospective trials carry more weight than retrospective reviews of past cases.
• Published averages describe those specific groups, not a guaranteed outcome for any one person.

Overall, available studies suggest that TACE may provide local control in selected patients, but evidence remains insufficient to establish it as routine standard treatment.

Accessing TACE for Pancreatic Cancer in Germany

Assessment for TACE in Germany begins with review of the diagnosis, pathology, imaging and previous treatment. The interventional team then determines whether the liver disease is technically treatable and whether TACE fits the overall treatment plan. Patients should have the following information available:

• Recent CT or MRI scans of the abdomen, with their reports.
• The pathology confirming the pancreatic cancer diagnosis.
• A summary of previous treatment, including chemotherapy.
• Recent blood and liver-function results.
• A current medication list, including any blood thinners.

If TACE is being considered for your pancreatic cancer treatment, TIG (Treatment in Germany) can help arrange a specialist review and connect you with a suitable treatment centre in Germany. The team can review your medical information and help coordinate the next steps if TACE is considered appropriate for your case.

References

1. Vogl TJ, Lilienthal C, Gruber-Rouh T, Afraz Z, Adwan H. Degradable Starch Microspheres Transarterial Chemoembolization with or without Lipiodol for Liver Metastases from Pancreatic Cancer: A Prospective Randomized Trial. Cancers. 2023;15(21):5239.

2. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy. BMC Cancer. 2024. doi:10.1186/s12885-024-12695-8.

3. Peng C, Xu B, Xiao J, Zhou C, Li X, Shi H, Qiang W, Wang T, Zhao J, Liu F, Li G, Li H, Chen C, Shi L. Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. Frontiers in Oncology. 2021;11:652426.

4. Conroy T, Ducreux M; ESMO Guidelines Committee. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer. ESMO Open. 2025;10(4):104528. 

5. Vogl TJ, Cojocaru R, Dahm DM, Adwan H. Interventional management of unresectable pancreatic cancer using transarterial chemoembolization and microwave ablation: a single-center evaluation over 12 years. J Cancer Res Clin Oncol. 2026;152(4):78. Published 2026 Mar 31. doi:10.1007/s00432-026-06463-3

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained